Agios Pharma (0HB0) Stock Statistics & Valuation Metrics
Total Valuation
Agios Pharma has a market cap or net worth of $1.82B. The enterprise value is $1.62B.
- Market Cap
- $1.82B
- Enterprise Value
- $1.62B
Share Statistics
Agios Pharma has 59,701,880 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 59,701,880
- Owned by Insiders
- 1.11%
- Owned by Institutions
- 50.19%
Financial Efficiency
Agios Pharma’s return on equity (ROE) is -0.35 and return on invested capital (ROIC) is -38.18%.
- Return on Equity (ROE)
- -0.35
- Return on Assets (ROA)
- -0.32
- Return on Invested Capital (ROIC)
- -38.18%
- Return on Capital Employed (ROCE)
- -0.39
- Revenue Per Employee
- 100.05K
- Profits Per Employee
- -764.41K
- Employee Count
- 540
- Asset Turnover
- 0.04
- Inventory Turnover
- 0.35
Valuation Ratios
The current PE Ratio of Agios Pharma is -4.36. Agios Pharma’s PEG ratio is 0.03.
- PE Ratio
- -4.36
- PS Ratio
- 18.55
- PB Ratio
- 1.77
- Price to FCF
- -4.99
- Price to Operating Cash Flow
- -5.04
- PEG Ratio
- 0.03
Income Statement
In the last 12 months, Agios Pharma had revenue of 54.03M and earned -412.78M in profits. Earnings per share was -7.12.
- Revenue
- 54.03M
- Gross Profit
- 42.51M
- Operating Income
- -472.13M
- Pretax Income
- -413.80M
- Net Income
- -412.78M
- EBITDA
- -408.62M
- Earnings Per Share (EPS)
- -7.12
Cash Flow
In the last 12 months, operating cash flow was -360.60M and capital expenditures -4.66M, giving a free cash flow of -365.25M billion.
- Operating Cash Flow
- -360.60M
- Free Cash Flow
- -365.25M
- Free Cash Flow per Share
- -6.14
Dividends & Yields
Agios Pharma pays an annual dividend of $0.29, resulting in a dividend yield of ―
- Dividend Per Share
- $0.29
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- -20.03%
- Earnings Yield
- -22.63%
Stock Price Statistics
- Beta
- 1.51
- 52-Week Price Change
- -28.96%
- 50-Day Moving Average
- 33.68
- 200-Day Moving Average
- 31.84
- Relative Strength Index (RSI)
- 37.84
- Average Volume (3m)
- 316
Important Dates
Agios Pharma upcoming earnings date is Nov 05, 2026, Before Open (Not Confirmed).
- Last Earnings Date
- Jul 30, 2026
- Next Earnings Date
- Nov 05, 2026
- Ex-Dividend Date
- Mar 15, 2022
Financial Position
Agios Pharma as a current ratio of 11.46, with Debt / Equity ratio of 3.37%
- Current Ratio
- 11.46
- Quick Ratio
- 11.06
- Debt to Market Cap
- 0.00
- Net Debt to EBITDA
- 0.12
- Interest Coverage Ratio
- 0.00
Taxes
In the past 12 months, Agios Pharma has paid -1.02M in taxes.
- Income Tax
- -1.02M
- Effective Tax Rate
- 0.00
Enterprise Valuation
Agios Pharma EV to EBITDA ratio is -4.21, with an EV/FCF ratio of -4.81.
- EV to Sales
- 17.85
- EV to EBITDA
- -4.21
- EV to Free Cash Flow
- -4.81
- EV to Operating Cash Flow
- -4.87
Balance Sheet
Agios Pharma has $617.58M in cash and marketable securities with $31.17M in debt, giving a net cash position of $586.40M billion.
- Cash & Marketable Securities
- $617.58M
- Total Debt
- $31.17M
- Net Cash
- $586.40M
- Net Cash Per Share
- $9.82
- Tangible Book Value Per Share
- $17.25
Margins
Gross margin is 87.92%, with operating margin of -466.78%, and net profit margin of -418.24%.
- Gross Margin
- 87.92%
- Operating Margin
- -466.78%
- Pretax Margin
- -419.27%
- Net Profit Margin
- -418.24%
- EBITDA Margin
- -423.84%
- EBIT Margin
- -429.29%
Analyst Forecast
The average price target for Agios Pharma is $45.20, which is 11.43% higher than the current price. The consensus rating is Strong Buy
- Price Target
- $45.20
- Price Target Upside
- 48.54% Upside
- Analyst Consensus
- Strong Buy
- Analyst Count
- 6
- Revenue Growth Forecast
- 140.58%
- EPS Growth Forecast
- -161.11%
Scores
- Smart Score
- 10
- AI Score
- ―